Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.49 |
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14169908 | 0.82 | ACE (0.43) | ACEMMETACR1HRH4OPRM1 | |
| SCHEMBL13626164 | 0.80 | MTNR1A (0.44) | MTNR1AMTNR1B | |
| SCHEMBL13625990 | 0.74 | MTNR1A (0.49) | ACEMMEMTNR1AMTNR1B | |
| SCHEMBL4799807 | 0.74 | MTNR1A (0.49) | ACEMMEMTNR1AMTNR1B | |
| SCHEMBL4799822 | 0.74 | MTNR1A (0.49) | ACEMMEMTNR1AMTNR1B | |
| SCHEMBL4738589 | 0.73 | ANPEP (0.49) | OPRM1OPRD1 | |
| SCHEMBL7694088 | 0.73 | FNTA (0.50) | ACEMMETACR1HRH4OPRM1 | |
| SCHEMBL6359193 | 0.72 | MTNR1A (0.79) | MTNR1AMTNR1B | |
| SCHEMBL7340929 | 0.70 | MTNR1A (0.42) | ACEMMEMTNR1AMTNR1B | |
| SCHEMBL28871636 | 0.70 | MTNR1A (0.50) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291998-A1 | EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291998-A1 | EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF | PSMC4, PSMB6, EPOR | ACE 1758/4885MME 486/4885MTNR1A 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.